Transgene reports durable disease-free survival for its individualized neoantigen vaccine TG4050 in head and neck cancer, while Elicio observes complete responses in metastatic pancreatic cancer following ELI-002 7P plus checkpoint inhibition.GlobeNewswireElicio Therapeutics
On the methodological front, new preprints validate AI-driven neoantigen prioritization frameworks, benchmark AlphaFold 3 for TCR specificity prediction, and identify CARM1 as a target to enhance dendritic cell cross-presentation.bioRxivbioRxivPubMed
Personalized neoantigen vaccines are an emerging strategy for cancer immunotherapy, but their effectiveness depends on selecting tumor-specific antigens capable of inducing functional T-cell responses. The VACINUS AI-informed neoantigen prioritization framework previously identif…
T cells are a key part of the adaptive immune system. Using their surface-bound T cell antigen receptors (TCRs), these cells scan peptides and other antigens presented to them by major histocompatibility complex molecules (MHCs) on the surface of cells, searching for abnormalitie…
The cancer-immunity cycle requires cross-presenting type I conventional dendritic cells (cDC1s) that induce T cell-mediated immunity, but therapeutic strategies for enhancing intratumoral cDC1 function are currently inadequate. We found the epigenetic enzyme CARM1 (coactivator-as…
Primary tumors and their sentinel lymph nodes are functionally linked sites of anti-tumor immunity, yet how T cell receptor (TCR) repertoires are organized across these compartments remains incompletely understood. We thus performed TCR{beta} sequencing on paired primary melanoma…
Relevant work from earlier we're still surfacing — not today's news.